10/27/22
Akorn Introduces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg at ASRM
08/16/22
Akorn Announces FDA-approved Generic Cetrorelix Acetate for Injection 0.25 mg
03/09/22
Akorn Announces Completion of the Sale of its Branded Ophthalmic Products to Théa Pharma
05/27/21
Akorn Announces Agreement to Sell its Consumer Health Business to Prestige Consumer Healthcare
05/10/21
Akorn Announces Two Key Executive Appointments
Events
Media Contact